Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Interferon-β-1b: a review of its use in multiple sclerosis.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
UCSF Seminar: "Antibody Repertoire Sequencing"
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Interferon beta for secondary progressive multiple sclerosis.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.

Pages